On March 26, 2024, the Supreme Court of the United States (SCOTUS) began hearing arguments in a case that could have potentially limited access to abortion pills throughout the country. On June 13, the court unanimously ruled that the plaintiffs did not have legal standing, and so the trial concluded and no added restrictions were placed on the pill.
The pill discussed in the case, called mifepristone, is one drug in a two-pill regimen commonly prescribed for medication abortions. The Supreme Court did not agree to discuss the drug's approval that has stood for more than 20 years. Rather, the court could have rolled back regulatory changes made by the Food and Drug Administration (FDA) to make it easier to access mifepristone. These changes include the ability to get the pill by mail without an in-person doctor's visit, for example.
